Cardiogeni is a UK-based clinical-stage biotech company founded by Nobel Laureate Professor Sir Martin Evans. Its mission is to develop regenerative cellular therapies for patients with heart failure, particularly those undergoing coronary artery bypass grafting (CABG). The company’s core innovation lies in its proprietary epigenetic reprogramming platform, which produces a novel class of allogeneic cell therapies known as iMP cells. The first product is CLXR-001, designed to regenerate damaged ....
